Danshensu alleviates bleomycin-induced pulmonary fibrosis by inhibiting lung fibroblast-to-myofibroblast transition via the MEK/ERK signaling pathway

References

• Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017;389(10082):1941–1952.
   PubMed Web of Science ®Google Scholar
• Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med. 2011;208(7):1339–1350.
   PubMed Web of Science ®Google Scholar
• Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810–816.
   PubMed Web of Science ®Google Scholar
• Khalil N, O’Connor R. Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment. Cmaj. 2004;171(2):153–160.
   PubMed Web of Science ®Google Scholar
• Li L, Cai L, Zheng L, et al. Gefitinib inhibits bleomycin-induced pulmonary fibrosis via alleviating the oxidative damage in mice. Oxid Med Cell Longev. 2018;2018:8249693.
   PubMed Web of Science ®Google Scholar
• Crystal RG, Bitterman PB, Rennard SI, et al. Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts). N Engl J Med. 1984;310(3):154–166.
   PubMed Web of Science ®Google Scholar
• Munger JS, Huang X, Kawakatsu H, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999;96(3):319–328.
   PubMed Web of Science ®Google Scholar
• Ramos C, Montaño M, García-Alvarez J, et al. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol. 2001;24(5):591–598.
   PubMed Web of Science ®Google Scholar
• Kim KK, Kugler MC, Wolters PJ, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci U S A. 2006;103(35):13180–13185.
   PubMed Web of Science ®Google Scholar
• Li X, Bi Z, Liu S, et al. Antifibrotic mechanism of cinobufagin in bleomycin-induced pulmonary fibrosis in mice. Front Pharmacol. 2019;10:1021.
   PubMed Web of Science ®Google Scholar
• Zhang K, Rekhter MD, Gordon D, et al. Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study. Am J Pathol. 1994;145(1):114–125.
   PubMed Web of Science ®Google Scholar
• Gabbiani G. The biology of the myofibroblast. Kidney Int. 1992;41(3):530–532.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang Q, Liu G, et al. Therapeutic potentials and mechanisms of the Chinese traditional medicine Danshensu. Eur J Pharmacol. 2019;864:172710.
   PubMed Web of Science ®Google Scholar
• Luo J, Zhang L, Zhang X, et al. Protective effects and active ingredients of Salvia miltiorrhiza Bunge extracts on airway responsiveness, inflammation and remodeling in mice with ovalbumin-induced allergic asthma. Phytomedicine. 2019;52:168–177.
   PubMed Web of Science ®Google Scholar
• Cao G, Zhu R, Jiang T, et al. Danshensu, a novel indoleamine 2,3-dioxygenase1 inhibitor, exerts anti-hepatic fibrosis effects via inhibition of JAK2-STAT3 signaling. Phytomedicine. 2019;63:153055.
   PubMed Web of Science ®Google Scholar
• Lu H, Tian A, Wu J, et al. Danshensu inhibits β-adrenergic receptors-mediated cardiac fibrosis by ROS/p38 MAPK axis. Biol Pharm Bull. 2014;37(6):961–967.
   PubMed Web of Science ®Google Scholar
• Ji Y, Wang T, Wei ZF, et al. Paeoniflorin, the main active constituent of Paeonia lactiflora roots, attenuates bleomycin-induced pulmonary fibrosis in mice by suppressing the synthesis of type I collagen. J Ethnopharmacol. 2013;149(3):825–832.
   PubMed Web of Science ®Google Scholar
• Vu TN, Chen X, Foda HD, et al. Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation. Respir Res. 2019;20(1):206.
   PubMed Web of Science ®Google Scholar
• Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998;157(4):1301–1315.
   PubMed Web of Science ®Google Scholar
• Canestaro WJ, Forrester SH, Raghu G, et al. Drug treatment of idiopathic pulmonary fibrosis: systematic review and network meta-analysis. Chest. 2016;149(3):756–766.
   PubMed Web of Science ®Google Scholar
• Galli JA, Pandya A, Vega-Olivo M, et al. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: tolerability and adverse drug reactions. Respirology. 2017;22(6):1171–1178.
   PubMed Web of Science ®Google Scholar
• Li LC, Kan LD. Traditional Chinese medicine for pulmonary fibrosis therapy: progress and future prospects. J Ethnopharmacol. 2017;198:45–63.
   PubMed Web of Science ®Google Scholar
• Jia J, Mo X, Liu J, et al. Mechanism of danshensu-induced inhibition of abnormal epidermal proliferation in psoriasis. Eur J Pharmacol. 2020;868:172881.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wu T, Chen JM, et al. Danshensu inhibits acetaldehyde-induced proliferation and activation of hepatic stellate cell-T6. Zhong Xi Yi Jie He Xue Bao. 2012;10: 1155–1161.
   Google Scholar
• Zhang N, Dong M, Luo Y, et al. Danshensu prevents hypoxic pulmonary hypertension in rats by inhibiting the proliferation of pulmonary artery smooth muscle cells via TGF-β-smad3-associated pathway. Eur J Pharmacol. 2018;820:1–7.
   PubMed Web of Science ®Google Scholar
• Chen YS, Lee SM, Lin YJ, et al. Effects of danshensu and salvianolic acid B from salvia miltiorrhiza bunge (lamiaceae) on cell proliferation and collagen and melanin production. Molecules. 2014;19(2):2029–2041.
   PubMed Web of Science ®Google Scholar
• Ji Y, Dou YN, Zhao QW, et al. Paeoniflorin suppresses TGF-β mediated epithelial-mesenchymal transition in pulmonary fibrosis through a Smad-dependent pathway. Acta Pharmacol Sin. 2016;37(6):794–804.
   PubMed Web of Science ®Google Scholar
• Wang G, Wu H, Liang P, et al. Fus knockdown inhibits the profibrogenic effect of cardiac fibroblasts induced by angiotensin II through targeting Pax3 thereby regulating TGF-β1/Smad pathway. Bioengineered. 2021;12(1):1415–1425.
   PubMed Web of Science ®Google Scholar
• Yang Y, Xiao C, Liu K, et al. Silencing of long noncoding INHBA antisense RNA1 suppresses proliferation, migration, and extracellular matrix deposition in human hypertrophic scar fibroblasts via regulating microRNA-141-3p/myeloid cell leukemia 1 axis. Bioengineered. 2021;12(1):1663–1675.
   PubMed Web of Science ®Google Scholar
• Li ZM, Xu SW, Liu PQ. Salvia miltiorrhizaBurge (Danshen): a golden herbal medicine in cardiovascular therapeutics. Acta Pharmacol Sin. 2018;39:802–824.
   PubMed Web of Science ®Google Scholar
• Shao R, Wang FJ, Lyu M, et al. Ability to suppress TGF-β-activated myofibroblast differentiation distinguishes the anti-pulmonary fibrosis efficacy of two danshen-containing chinese herbal medicine prescriptions. Front Pharmacol. 2019;10:412.
   PubMed Web of Science ®Google Scholar
• Bartram U, Speer CP. The role of transforming growth factor beta in lung development and disease. Chest. 2004;125(2):754–765.
   PubMed Web of Science ®Google Scholar
• Kim KK, Sheppard D, Ha C. TGF-β1 signaling and tissue fibrosis. Cold Spring Harb Perspect Biol. 2018;10(4):a022293.
   Web of Science ®Google Scholar
• Ignotz RA, Massagué J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem. 1986;261(9):4337–4345.
   PubMed Web of Science ®Google Scholar
• Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A. 1986;83(12):4167–4171.
   PubMed Web of Science ®Google Scholar
• Kulkarni AB, Huh CG, Becker D, et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A. 1993;90(2):770–774.
   PubMed Web of Science ®Google Scholar
• Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 1992;359(6397):693–699.
   PubMed Web of Science ®Google Scholar
• Travis MA, Sheppard D. TGF-β activation and function in immunity. Annu Rev Immunol. 2014;32(1):51–82.
   PubMedGoogle Scholar
• Vannella KM, Wynn TA. Mechanisms of organ injury and repair by macrophages. Annu Rev Physiol. 2017;79(1):593–617.
   PubMedGoogle Scholar
• Minutti CM, Knipper JA, Allen JE, et al. Tissue-specific contribution of macrophages to wound healing. Semin Cell Dev Biol. 2017;61:3–11.
   PubMed Web of Science ®Google Scholar
• Krafts KP. Tissue repair: the hidden drama. Organogenesis. 2010;6(4):225–233.
   PubMed Web of Science ®Google Scholar
• Thannickal VJ, Lee DY, White ES, et al. Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem. 2003;278(14):12384–12389.
   PubMed Web of Science ®Google Scholar
• Gauldie J, Sime PJ, Xing Z, et al. Transforming growth factor-beta gene transfer to the lung induces myofibroblast presence and pulmonary fibrosis. Curr Top Pathol. 1999;93: 35–45.
   Google Scholar
• Liu G, Zhang Q, Zhang J, et al. Preventive but nontherapeutic effect of danshensu on hypoxic pulmonary hypertension. J Int Med Res. 2020;48(5):300060520914218.
   Web of Science ®Google Scholar
• Qu W, Huang H, Li K, et al. Danshensu-mediated protective effect against hepatic fibrosis induced by carbon tetrachloride in rats. Pathol Biol. 2014;62(6):348–353.
   PubMedGoogle Scholar
• Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659–661.
   PubMed Web of Science ®Google Scholar
• Chen H, Chen H, Liang J, et al. TGF-β1/IL-11/MEK/ERK signaling mediates senescence-associated pulmonary fibrosis in a stress-induced premature senescence model of Bmi-1 deficiency. Exp Mol Med. 2020;52(1):130–151.
   PubMed Web of Science ®Google Scholar
• Galuppo M, Esposito E, Mazzon E, et al. MEK inhibition suppresses the development of lung fibrosis in the bleomycin model. Naunyn-Schmiedeberg’s Arch Pharmacol. 2011;384(1):21–37.
   Google Scholar
• Madala SK, Schmidt S, Davidson C, et al. MEK-ERK pathway modulation ameliorates pulmonary fibrosis associated with epidermal growth factor receptor activation. Am J Respir Cell Mol Biol. 2012;46(3):380–388.
   PubMed Web of Science ®Google Scholar
• Ye T, Xiong D, Chen L, et al. Effect of Danshen on TLR2-triggered inflammation in macrophages. Phytomedicine. 2020;70:153228.
   PubMed Web of Science ®Google Scholar
• Tang F, Zhou X, Wang L, et al. A novel compound DT-010 protects against doxorubicin-induced cardiotoxicity in zebrafish and H9c2 cells by inhibiting reactive oxygen species-mediated apoptotic and autophagic pathways. Eur J Pharmacol. 2018;820:86–96.
   PubMed Web of Science ®Google Scholar